Report: Antidiabetics - Diabetes market growth driven by epidemiological trends and rich pipeline

Oct. 9, 2010 - PRLog -- Datamonitor expects the antidiabetics market to grow to $34.8 billion in 2019 for the seven major markets. Januvia will become the leading franchise from 2012 after patent expiry of Actos, with franchise sales reaching nearly $6 billion by 2019. Pipeline candidates will make up 30% of sales in 2019, with once-weekly GLP-1 agonists and new long-acting insulin analogs meeting success.

Scope

* Description of the competitive landscape in antidiabetics across seven major markets with market definition and overview
* Event-driven updated sales forecasts for 2010-19 across the seven major markets: US, France, Germany, Italy, Spain, UK and Japan
* Analysis of major events and brand dynamics affecting the diabetes market
* Understand the barriers to uptake for novel antidiabetics agents and quantify the shift away from older therapies like glitazones and sulfonylureas

Highlights

The antidiabetics market in the seven major markets is expected to grow from $22,806 million in 2009 to $34,820 million in 2019, with a 4% CAGR. Growth is driven by the epidemiological expansion of the market, fuelled by the obesity epidemic and improved diagnosis rates.

Januvia will be the leading oral antidiabetic agent after the patent expiry of Actos. Its relatively benign safety profile has led to rapid growth since launching in 2006, despite a poorer efficacy than other oral antidiabetics. Marketed and pipeline class competitors are seen as ""me-too"" drugs and will struggle to attract share away from Januvia.

New products launched from the highly active antidiabetic pipeline will command 30% ($10,570m) of the market in 2019. Highest growth will be seen for the GLP-1 agonists, with the first once-weekly product, Bydureon, expected to take share from within the class, insulins and oral antidiabetics.

Reasons to Purchase

* Quantify the future size of the antidiabetics market from 2010-2019 and identify opportunities for new products
* Examine the future performance of leading antidiabetic brands and the growth of generics and insulin biosimilars
* Understand the barriers to uptake for novel antidiabetic agents

For more information or to purchase this report, go to:
-  http://www.fastmr.com/prod/87534_forecast_insight_antidia...

Partial Table of Contents:

TABLE OF CONTENTS
Overview 1
Catalyst 1
Summary 1
About Datamonitor healthcare 2
About the Cardiovascular and diabetes pharmaceutical analysis team 2
Executive Summary 3
Strategic scoping and focus 3
Datamonitor insight into the disease market 3
Related reports 4
Upcoming related reports 4

1. MARKET DEFINITION AND OVERVIEW 10
Market definition for this report 10
Countries and regions included in this report 10
Seven major market assessment 11
Rest of the World snapshot 31

2. EPIDEMIOLOGY OF DIABETES 35
Introduction 35
Key points 35
Disease definition, classification and diagnosis criteria 36
Strengths and weaknesses of our epidemiologic projections 38
Risk factors of type 1 diabetes 38
Global variation and temporal trends of incidence and prevalence of diabetes mellitus 40
Epidemiologic forecasting of type 1 diabetes mellitus 41
Results for type 1 diabetes incidence 43
Risk factors of type 2 diabetes 45
Co-morbidities of type 2 diabetes 46
Epidemiologic forecasting of type 2 diabetes mellitus 47
Results for type 2 diabetes prevalence 51
Discussion 59

3. BRAND DYNAMICS 61
Overview of the competitive landscape in antidiabetics 61
Basal insulins 63
Fast-acting insulins 69
Premixed insulins 78
Glitazones 80
DPP-4 inhibitors 87
GLP-1 agonists 96
Other classes 103

Bibliography 108
Journal papers 108
Websites 108
Datamonitor reports 109
Type 1 diabetes epidemiology references 109
Type 2 diabetes epidemiology references 111
Appendix A - Market Assumptions 115
New product launches 115
Patent expiries 117
Data definitions, limitations and assumptions 117
Forecast methodology 119
Appendix B 120
Contributing experts 120
Conferences attended 120
Report methodology 120
About Datamonitor 120
Disclaimer 124

TABLE OF FIGURES
Figure 1: Antidiabetics sales ($m) by type of product (marketed versus pipeline) in the seven major markets, 2006-2019 13
Figure 2: Antidiabetics sales (SUm) by type of product (marketed versus pipeline) in the seven major markets, 2006-2019 14
Figure 3: Antidiabetics sales ($m) by type of product (branded versus generic) in the seven major markets, 2006-2019 15
Figure 4: Antidiabetics sales (SUm) by type of product (branded versus generic) in the seven major markets, 2006-2019 16
Figure 5: Antidiabetics sales ($m) by country in the seven major markets, 2006-2019 18
Figure 6: Antidiabetics sales (SUm) by country in the seven major markets, 2006-2019 19
Figure 7: Antidiabetics sales ($m) and historical and forecast growth (% CAGR) by region in the seven major markets, 2006-2019 20
Figure 8: Regional sales performance in the seven major diabetes markets, 2008-09 21
Figure 9: Antidiabetics sales ($m) by class in the seven major markets, 2006-2019 22
Figure 10: Antidiabetics sales (SUm) by class in the seven major markets, 2006-2019 23
Figure 11: Insulin sales ($m) for diabetes by class in the seven major markets, 2006-2019 24
Figure 12: Performance of the antidiabetic drug classes across the seven major markets, 2006-09 25
Figure 13: Performance of antidiabetic drug classes including pipeline drugs across the seven major markets, 2010-19 26

Full Table of Contents is available at:
-- http://www.fastmr.com/catalog/product.aspx?productid=8753...

About Datamonitor

The Datamonitor Group is a world-leading provider of premium global business information, delivering independent data, analysis and opinion across the Automotive, Consumer Markets, Energy & Utilities, Financial Services, Logistics & Express, Pharmaceutical & Healthcare, Retail, Technology and Telecoms industries. Datamonitor's market intelligence products and services ensure that you will achieve your desired commercial goals by giving you the insight you need to best respond to your competitive environment.  View more research from Datamonitor at http://www.fastmr.com/catalog/publishers.aspx?pubid=1002

About Fast Market Research

Fast Market Research is an online aggregator and distributor of market research and business information. We represent the world's top research publishers and analysts and provide quick and easy access to the best competitive intelligence available.

For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.

# # #

Fast Market Research is an online aggregator and distributor of market research and business information. We represent the world's top research publishers and analysts and provide quick and easy access to the best competitive intelligence available.